However, it's important to note that the use of Melanotan II for this purpose is controversial and not approved for human use in many countries due to safety concerns
spending on GLP-1s soared: total annual spending reached nearly $72 billion in 2023 ( [20] ) and climbed to approximately $52.7 billion in US market revenue in 2025 (accounting for 75.3% of the global GLP-1 market), with projections pointing toward $155.9 billion by 2033 ( [21] )
At the same time, this broader literature highlights an important nuance: although wettability is a powerful determinant, surface texture/topography often remains a major modifier of bacterial adhesion
If you have established atherosclerotic cardiovascular disease, a GLP-1 receptor agonist with proven cardiovascular benefit would be appropriate
Using it longer means the overall cost will grow compared to medicines used for a short time
Vitamin B12 injections usually contain high levels of this substance, which works to raise vitamin B12 levels in the blood